Engineered E. coli for Parallel Antigen and Adjuvant Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing bacterial vaccines are laborious and costly, particularly in synthesizing glycoconjugate vaccines, and lack the ability to efficiently produce complex carbohydrate antigens and lipid A adjuvants in parallel.
Innovation Solution
Engineered E. coli strains are developed to produce a diverse library of lipid A moieties linked to antigens, using lipid modification polynucleotides such as lpxE, lpxF, lpxO, lpxR, pagL, and pagP, allowing for the simultaneous synthesis of antigens and adjuvants within the bacterium, reducing production time and costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to synthesize glycoconjugate vaccines, then vaccine components can be produced, but the process is laborious and costly with inability to produce antigens and adjuvants in parallel
Solution Approach 1:
The patent merges the separate production processes of antigens and adjuvants into a single bacterial system. Engineered E. coli strains simultaneously produce both components within the same cell, eliminating the need for separate synthesis pipelines and enabling parallel production of vaccine components.
Solution Approach 2:
The engineered bacterial strains serve multiple functions: they act as factories for antigen production, adjuvant synthesis, and self-assembly into vaccine particles. This multi-functionality replaces multiple specialized production systems with a single versatile platform.
2Loss of time
If complex carbohydrate antigens are synthesized through traditional chemical methods, then antigens can be produced, but the process is tedious and time-consuming
Solution Approach 1:
The patent replaces complex chemical synthesis mechanisms with biological synthesis pathways. Engineered bacteria use their natural metabolic and enzymatic systems to produce carbohydrate antigens, avoiding tedious chemical reactions and purification steps required by traditional methods.
Solution Approach 2:
The engineered bacterial strains possess self-service capabilities for antigen production. The bacteria automatically synthesize, modify, and assemble carbohydrate antigens using their own enzymatic machinery, eliminating the need for external chemical intervention and manual processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid and cost-effective generation of whole vaccines with tailored immune responses by co-localizing lipid A moieties with antigens on the bacterial surface, facilitating the production of vaccines for various pathogens such as influenza and cholera.
Implementation Method 1
lipid modification polynucleotides selected from the group consisting of lpxE, lpxF, lpxO, lpxR, pagL, and pagP polynucleotides
Data Source
AI summary
Engineered bacteria are provided that produce modified lipid A and a polypeptide or polysaccharide antigens. In some aspects, immunogenic compositions are provided comprising a modified a lipid A and a polypeptide or polysaccharide antigen.